
    
      Three groups of females (3000, 1500 and 1500 subjects, respectively) were injected 3 times
      (at months 0, 1 and 6) with the herpes simplex vaccine, the HavrixTM vaccine (control) and a
      Saline solution (placebo), respectively. Subjects were followed over 18 months.
    
  